Gregory Basarab

List of Publications by Year
in descending order

60 papers	1,834 citations	236925 25 h-index	289244 40 g-index
65 all docs	65 docs citations	65 times ranked	2127 citing authors

#	Article	IF	Citations
1	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin Inhibition. Journal of Medicinal Chemistry, 2022, 65, 3371-3387.	6.4	3
2	Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones. Antimicrobial Agents and Chemotherapy, 2022, 66, e0219221.	3.2	13
3	Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. Journal of Medicinal Chemistry, 2022, 65, 6903-6925.	6.4	16
4	Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box. Nature Communications, 2021, 12, 269.	12.8	61
5	Antitubercular 2-Pyrazolylpyrimidinones: Structureâ€“Activity Relationship and Mode-of-Action Studies. Journal of Medicinal Chemistry, 2021, 64, 719-740.	6.4	9
6	Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts. Journal of Medicinal Chemistry, 2021, 64, 2291-2309.	6.4	11
7	1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 12790-12807.	6.4	13
8	Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model. Journal of Medicinal Chemistry, 2020, 63, 13013-13030.	6.4	11
9	Structural Basis for Inhibitor Potency and Selectivity of Plasmodium falciparum Phosphatidylinositol 4-Kinase Inhibitors. ACS Infectious Diseases, 2020, 6, 3048-3063.	3.8	14
10	Antibacterial Spiropyrimidinetriones with N-Linked Azole Substituents on a Benzisoxazole Scaffold Targeting DNA Gyrase. Journal of Medicinal Chemistry, 2020, 63, 11882-11901.	6.4	11
11	Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Doseâ€“Response Curves against Multidrug Resistant Parasite Strains. Journal of Medicinal Chemistry, 2018, 61, 9371-9385.	6.4	9
12	Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
13	Plasmodial Kinase Inhibitors: License to Cure?. Journal of Medicinal Chemistry, 2018, 61, 8061-8077.	6.4	49
14	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
15	Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria. European Journal of Medicinal Chemistry, 2018, 157, 610-621.	5.5	10
16	Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria. Journal of Medicinal Chemistry, 2018, 61, 5692-5703.	6.4	40
17	Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents. Xenobiotica, 2017, 47, 31-49.	1.1	6
18	Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic. Topics in Medicinal Chemistry, 2017, , 165-188.	0.8	1

#	Article	IF	Citations
19	Development and design of the tertiary amino effect reaction for DNA-encoded library synthesis. MedChemComm, 2016, 7, 1316-1322.	3.4	26
20	Expedient synthesis of tetrahydroquinoline-3-spirohydantoin derivatives via the Lewis acid-catalyzed tert-amino effect reaction. Chemical Communications, 2016, 52, 8541-8544.	4.1	27
21	Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Scientific Reports, 2015, 5, 11827.	3.3	85
22	In vitroandin vivometabolism of¹⁴C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase. Xenobiotica, 2015, 45, 158-170.	1.1	3
23	Design of Antibacterial Agents. , 2015, , 611-626.		0
24	Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. Journal of Biological Chemistry, 2015, 290, 20984-20994.	3.4	34
25	Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914). Journal of Medicinal Chemistry, 2015, 58, 6264-6282.	6.4	60
26	Structural Insights Lead to a Negamycin Analogue with Improved Antimicrobial Activity against Gram-Negative Pathogens. ACS Medicinal Chemistry Letters, 2015, 6, 930-935.	2.8	10
27	In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 467-474.	3.2	67
28	Illicit Transport via Dipeptide Transporter Dpp is Irrelevant to the Efficacy of Negamycin in Mouse Thigh Models ofEscherichia coliInfection. ACS Infectious Diseases, 2015, 1, 222-230.	3.8	9
29	Synthesis of a Tetrahydronaphthyridine Spiropyrimidinetrione DNA Gyrase Inhibiting Antibacterial Agent - Differential Substitution at all Five Carbon Atoms of Pyridine.. Organic Letters, 2014, 16, 6456-6459.	4.6	25
30	Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosome. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16274-16279.	7.1	36
31	Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization. Journal of Medicinal Chemistry, 2014, 57, 9078-9095.	6.4	44
32	Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099). Journal of Medicinal Chemistry, 2014, 57, 6060-6082.	6.4	57
33	Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents. Journal of Medicinal Chemistry, 2013, 56, 8712-8735.	6.4	75
34	Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailabilty. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5600-5607.	2.2	14
35	Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7416-7420.	2.2	109
36	Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): Pyridodiazepine amines. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 930-936.	2.2	41

#	Article	IF	Citations
37	Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: A novel pro-drug approach to increase exposure. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4716-4722.	2.2	31
38	Roles of Substrate Distortion and Intramolecular Hydrogen Bonding in Enzymatic Catalysis by Scytalone Dehydratase. Biochemistry, 2002, 41, 820-826.	2.5	16
39	Design of Inhibitors of Scytalone Dehydratase: Probing Interactions with an Asparagine Carboxamide. Bioorganic and Medicinal Chemistry, 2002, 10, 4143-4154.	3.0	13
40	Structure-based design of inhibitors of the rice blast fungal enzyme trihydroxynaphthalene reductase. Journal of Molecular Graphics and Modelling, 2001, 19, 434-447.	2.4	37
41	Structures of Trihydroxynaphthalene Reductase-Fungicide Complexes. Structure, 2001, 9, 19-27.	3.3	42
42	Selection of a potent inhibitor of trihydroxynaphthalene reductase by sorting disease control data. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 491-494.	2.2	12
43	Binding dynamics of two water molecules constrained within the scytalone dehydratase binding pocket. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 23-26.	2.2	10
44	Cyclobutane carboxamide inhibitors of fungal melanin: biosynthesis and their evaluation as fungicides. Bioorganic and Medicinal Chemistry, 2000, 8, 897-907.	3.0	38
45	Stereochemistry of the Enolization of Scytalone by Scytalone Dehydratase. Biochemistry, 2000, 39, 2276-2282.	2.5	25
46	Solvolytic Enolization of Scytalone. Organic Letters, 2000, 2, 1541-1544.	4.6	6
47	Tight Binding Inhibitors of Scytalone Dehydratase:Â Effects of Site-Directed Mutations. Biochemistry, 2000, 39, 8593-8602.	2.5	19
48	Design of scytalone dehydratase inhibitors as rice blast fungicides: (N-phenoxypropyl)-carboxamides. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1607-1612.	2.2	32
49	Design of scytalone dehydratase inhibitors as rice blast fungicides: Derivatives of norephedrine. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1613-1618.	2.2	34
50	Catalytic mechanism of scytalone dehydratase fromMagnaporthe grisea. Pest Management Science, 1999, 55, 277-280.	0.4	10
51	High-resolution structures of scytalone dehydratase-inhibitor complexes crystallized at physiological pH. , 1999, 35, 425-439.		35
52	Catalytic Mechanism of Scytalone Dehydratase:Â Site-Directed Mutagenisis, Kinetic Isotope Effects, and Alternate Substrates. Biochemistry, 1999, 38, 6012-6024.	2.5	43
53	Wild-Type Enzyme as a Reporter of Inhibitor Binding by Catalytically Impaired Mutant Enzymes. Biochemical and Biophysical Research Communications, 1999, 263, 617-620.	2.1	4
54	2,3-Dihydro-2,5-dihydroxy-4H-benzopyran-4-one: A Nonphysiological Substrate for Fungal Melanin Biosynthetic Enzymes. Analytical Biochemistry, 1998, 256, 1-6.	2.4	22

#	Article	IF	Citations
55	Structure-Based Design of Potent Inhibitors of Scytalone Dehydratase:Â Displacement of a Water Molecule from the Active Siteâ€¡. Biochemistry, 1998, 37, 17735-17744.	2.5	131
56	Synthesis of Agrochemicals and Agricultural Biotechnology Entering the 21st Century. ACS Symposium Series, 1998, , 1-5.	0.5	1
57	Trihydroxynaphthalene Reductase fromMagnaporthegrisea:Â Realization of an Active Center Inhibitor and Elucidation of the Kinetic Mechanism. Biochemistry, 1997, 36, 1852-1860.	2.5	47
58	Crystal structure of scytalone dehydratase â€" a disease determinant of the rice pathogen, Magnaporthe grisea. Structure, 1994, 2, 937-944.	3.3	143
59	The chemistry and biological activity of a new class of azole fungicides: 1-amino-1,2,4-triazoles. Pest Management Science, 1991, 31, 403-417.	0.4	9
60	Biologically Active Organosilicon Compounds. ACS Symposium Series, 1987, , 288-301.	0.5	21